(Taken directly from the application) CFTR mediates the conductance of chloride ions across the apical membrane of epithelial cells. When it is dysfunctional or absent from this membrane due to mutations in the CFTR gene, epithelial surfaces are improperly hydrated so that viscous mucous secretions accumulate and the resultant disease pathology ensues. Many of the more than 500 disease causing mutations, including the most common, delta F508, present in more than 90% of patients, prevent the protein from reaching the apical membrane. The delta F508 protein is synthesized and can function as a regulated Cl-channel but does not proceed beyond the endoplasmic reticulum (ER). Both the wild-type and the delta F508 protein are rapidly degraded (T 1/2 about 1/2 h) at the ER but about 25% of the wild type molecules achieve a mature conformation enabling them to escape degradation and be transported to the Golgi. The objective of this proposal is to gain a better understanding of the factors which are responsible for the maintenance of a positive balance between maturation and degradation and to identify the rate limiting step in transport from ER to Golgi. This will be done through five specific aims. First, the degradation pathways will be characterized in more detail. We have recently shown that the ubiquitin-proteasome pathway plays an important role but there are others to be identified. Proteasome inhibition does not augment maturation of delta F508 but inhibition of the other proteolytic mechanisms might. Second, the influence of modifications that occur at the ER during synthesis will be elucidated. The efficiency of maturation of the wild-type protein can be improved by altering the number and location of N-glycosylation sites which are used and by dephosphorylation. The influence of these modifications on delta F508 synthesis will now be tested. Third, we shall identify chaperones (in addition to calnexin and hsc70) which interact with CFTR at the ER and attempt to manipulate these interactions as we have done with calnexin. Fourth, we shall further test the hypothesis that a complete native tertiary structure of the cytoplasmic aspect of CFTR is required for it to be recognized as competent for exit from the ER. Fifth, we shall explore an alternative model to the active retention of delta F508 CFTR at the ER. Instead, the mutant molecule would be defective in recognition by the ER to Golgi vesicular transport machinery. We shall identify components of this mechanism which control CFTR export, employing a new in vitro assay which reconstitutes vesicle budding from ER microsomes. The potential role of a specific family of chaperones (p24/25) in """"""""escorting"""""""" CFTR during export will also be examined.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK051870-04
Application #
2905933
Study Section
Special Emphasis Panel (SRC (06))
Program Officer
Mckeon, Catherine T
Project Start
1996-09-30
Project End
2000-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Arizona
Department
Type
DUNS #
City
Scottsdale
State
AZ
Country
United States
Zip Code
85259
Wang, Chao; Balch, William E (2018) Bridging Genomics to Phenomics at Atomic Resolution through Variation Spatial Profiling. Cell Rep 24:2013-2028.e6
Hutt, Darren M; Mishra, Sanjay Kumar; Roth, Daniela Martino et al. (2018) Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy. J Biol Chem 293:13682-13695
Hutt, Darren M; Loguercio, Salvatore; Campos, Alexandre Rosa et al. (2018) A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease. J Mol Biol 430:2951-2973
Yang, Zhengrong; Hildebrandt, Ellen; Jiang, Fan et al. (2018) Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1. Biochim Biophys Acta Biomembr 1860:1193-1204
Hutt, Darren M; Loguercio, Salvatore; Roth, Daniela Martino et al. (2018) Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation. J Biol Chem 293:13477-13495
Subramanian, Kanagaraj; Rauniyar, Navin; Lavalleé-Adam, Mathieu et al. (2017) Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease. Mol Cell Proteomics 16:1938-1957
Ma, Pikyee; Weichert, Dietmar; Aleksandrov, Luba A et al. (2017) The cubicon method for concentrating membrane proteins in the cubic mesophase. Nat Protoc 12:1745-1762
Wang, Chao; Bouchecareilh, Marion; Balch, William E (2017) Measuring the Effect of Histone Deacetylase Inhibitors (HDACi) on the Secretion and Activity of Alpha-1 Antitrypsin. Methods Mol Biol 1639:185-193
Das, Jhuma; Aleksandrov, Andrei A; Cui, Liying et al. (2017) Transmembrane helical interactions in the CFTR channel pore. PLoS Comput Biol 13:e1005594
Budinger, G R Scott; Kohanski, Ronald A; Gan, Weiniu et al. (2017) The Intersection of Aging Biology and the Pathobiology of Lung Diseases: A Joint NHLBI/NIA Workshop. J Gerontol A Biol Sci Med Sci 72:1492-1500

Showing the most recent 10 out of 47 publications